Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Cuendet

Showing results (71-80 of 74) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 74 results.
Frontiers in Oncology|December 26, 2022
A differential process mining analysis of COVID-19 management for cancer patientsMichel A Cuendet, Roberto Gatta, Alexandre Wicky, et al.
International Journal of Environmental Research and Public Health|September 16, 2020
What Role Can Process Mining Play in Recurrent Clinical Guidelines Issues? A Position PaperRoberto Gatta, Mauro Vallati, Carlos Fernandez-Llatas, et al.
Nature Cancer|February 5, 2022
Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanomaLisa Haas, Anais Elewaut, Camille L Gerard, et al.
European Journal of Cancer (Oxford, England : 1990)|April 17, 2021
Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapyE Ghisoni, A Wicky, H Bouchaab, et al.
Pageof 8

Showing results (71-80 of 74) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 74 results.
Frontiers in Oncology|December 26, 2022
A differential process mining analysis of COVID-19 management for cancer patientsMichel A Cuendet, Roberto Gatta, Alexandre Wicky, et al.
International Journal of Environmental Research and Public Health|September 16, 2020
What Role Can Process Mining Play in Recurrent Clinical Guidelines Issues? A Position PaperRoberto Gatta, Mauro Vallati, Carlos Fernandez-Llatas, et al.
Nature Cancer|February 5, 2022
Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanomaLisa Haas, Anais Elewaut, Camille L Gerard, et al.
European Journal of Cancer (Oxford, England : 1990)|April 17, 2021
Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapyE Ghisoni, A Wicky, H Bouchaab, et al.
Pageof 8